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Abstract Protein kinase A (PKA) has been proposed to
regulate the signal transduction through the Ras/extracellular-
regulated kinase (ERK) pathway. Here we demonstrate that
when the PKA activity was inhibited prior to growth factor
stimulus the signal flow through the Ras/ERK pathway was
significantly increased. Furthermore, the data indicated that this
PKA-mediated regulation was simultaneously targeted to the
upstream kinase Raf-1 and to the ERK-specific phosphatase
mitogen-activated protein kinase phosphatase-1 (MKP-1).
Moreover, our data suggested that the level of PKA activity
determined the transcription rate of mkp-1 gene, whereas the
Ras/ERK signal was required to protect the MKP-1 protein
against degradation. These results point to a tight regulatory
relationship between PKA and the growth factor signaling, and
further suggest an important role for basal PKA activity in such
regulation. We propose that PKA adjusts the activity of the
Ras/ERK pathway and maintains it within a physiologically
appropriate level. + 2002 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
Binding of growth factors to the transmembrane receptor
leads to activation of intracellular signaling pathways. The
main pathway transporting these signals is the Ras/extracellu-
lar-regulated kinase (ERK) pathway. Depending on the na-
ture of the extracellular stimulus, activation of the Ras/ERK
pathway may contribute to cell growth, di¡erentiation or sur-
vival. Tailored responses to distinct extracellular stimuli are
presumably generated by integration of di¡erent signals in the
cell. Such integration comprises, at least in part, a ¢rm control
of signal magnitude and duration [1^4]. The molecular mech-
anisms of such regulation are not completely understood but
likely involve cross-talk between di¡erent mitogen-activated
protein (MAP) kinase cascades as well as protein kinases of
other signaling pathways such as protein kinase A (PKA) and
protein kinase C [5,6].
Recent studies suggest that cAMP and PKA participate in
the regulation of the growth factor signaling [7^10]. The main
molecular mediators of such regulation are the Raf-1 and
B-Raf serine/threonine kinases [11,12]. In most cell types
PKA down-regulates the Ras/ERK signaling by interfering
with the Ras-mediated activation of Raf-1 [11,13^16]. How-
ever, in melanocytes and in PC12 cells an increase in the
cAMP concentration activates the Ras/ERK pathway through
the small GTP binding protein Rap-1 and/or B-Raf [17^21].
The kinase intermediates of the Ras/ERK pathway, such as
ERK1 and ERK2, are regulated by phosphorylation and de-
phosphorylation of speci¢c amino acid residues [22^28]. The
family of dual speci¢c MAP kinase phosphatases (MKPs),
able to dephosphorylate both threonine and tyrosine residues,
is an important phosphatase family involved in the direct
down-regulation of MAPK signaling. According to their pat-
tern of transcriptional regulation and cellular localization,
MKPs are divided into two categories: nuclear proteins en-
coded by immediate early genes (e.g. MKP-1 and MKP-2)
and cytosolic proteins encoded by delayed genes (e.g. MKP-
3/Pyst1). Consequently, MKP-1 and MKP-2 are the most im-
portant early regulators of mitogen-induced ERK activity.
The abundance of MKP proteins is controlled by the tran-
scriptional activation of the gene and by the ubiquitin-directed
degradation of the protein product [29^33]. MKP-1, MKP-2
and MKP-3 are transiently expressed following activation of
the Ras/ERK pathway, suggesting a feedback loop to regulate
ERK activity [34^40]. MKP-1 and MKP-2 dephosphorylate
all mitogen-activated kinases albeit their substrate preferences
depend on the cell model studied, whereas MKP-3 is speci¢c
for ERK1 and ERK2 [41^46]. PKA controls the function of
several phosphatases able to dephosphorylate various compo-
nents of the Ras/ERK pathway. Such phosphatases include
serine/threonine phosphatase PP1 and tyrosine phosphatases
PTP-SL and HePTP [47^49]. Moreover, PKA directly regu-
lates the transcription of mkp-1 gene via two cAMP response
elements (CRE) located in its promoter region [50^52].
Although PKA is believed to have a critical role in the
growth factor-induced Ras/ERK signaling, the mechanisms
and physiological signi¢cance of such regulation are incom-
pletely understood. Whereas accumulating evidence suggests
that experimental over-activation of PKA down-regulates the
Ras/ERK signaling, the role of basal PKA activity in the
regulation of growth factor signaling remains unknown. We
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have previously shown that in NIH3T3 ¢broblasts active
PKA is required for the ¢broblast growth factor-2 (FGF-2)-
mediated activation of an AP-1 driven gene transcription
[53,54]. In this paper, we demonstrate that the down-regula-
tion of PKA activity allows dramatic increase in the signal
transduction through the Ras/ERK pathway in response to
growth factor stimuli, showing that a strict control over the
PKA activity is required to maintain the proper signal £ow
through this pathway. Our data indicate that PKA adjusts the
magnitude and duration of growth factor signals by control-
ling the catalytic activity of Raf-1 and the expression of
MKP-1. We further elucidated mechanisms by which PKA
and growth factors co-operatively regulated the expression
and function of MKP-1. In conclusion, our data suggest an
important role for controlled PKA activity in the regulation
of growth factor signaling.
2. Materials and methods
2.1. Materials
H89 (N-[2-(p-bromocinnamylamino)-ethyl]-5-isoquinolinesulfon-
amide) (used at 10 WM), 8-BrcAMP (8-bromoadenosine 3P,5P-cyclic
monophosphate) (used at 500 WM), anisomycin, PD98059, cyclohex-
imide and MG132 were purchased from Calbiochem. Basic FGF
(FGF-2) and epidermal growth factor (EGF) were from PeproTech
(Rocky Hill, NJ, USA) and were used at the concentration of 10 ng/
ml. Protein-G Sepharose0 Fast Flow and glutathione-Sepharose0
were from Pharmacia Biotech. The monoclonal antibody for activated
ERK1 and ERK2, myelin basic protein (MBP) and 4-hydroxytamox-
ifen (4-OHT) were purchased from Sigma. Agarose-conjugated Raf-1
(C-12:sc-133Ac), Raf-1 (C-12), MKP-1 (V-15), MKP-3 (C-20) and
ERK2 (K-23) antibodies and MEK-1 (FL-1) protein were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-p38
and anti-phospho-p38 antibodies were from New England Biolabs
(UK), and MKP-2 antibody from Transduction Laboratories (Lex-
ington, KY, USA). Anti-glutathione S-transferase (GST) antibody
was from Upstate Biotechnology (USA).
2.2. Cell culture and transfections
The mouse ¢broblast cells (NIH3T3) were routinely cultured in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
5% fetal calf serum (FCS) and 1% (w/v) penicillin and streptomycin
in humidi¢ed 95% air, 5% CO2 at 37‡C. When the cultures reached
V80% con£uence cells were serum-starved with DMEM supple-
mented with 1% carboxymethyl-Sepharose-eluted FCS for 48 h and
treated with growth factors and chemicals. Plasmid DNA was trans-
fected to the cells by the calcium-phosphate precipitation method.
Stably transfected cells were produced by simultaneous introduction
of the pBGS plasmid and a 10U molar excess of pEBG-ERK2 plas-
mid (kindly provided by Dr. Michyuki Matsuda) and subsequent
selection with G418 (500 Wg/ml). The cDNA encoding vRaf-
1:ER[DD] (a generous gift by Dr. Martin McMahon) was cloned
into the pCDNA6 vector and transfected cells were selected on the
basis of their resistance to blasticidin (1 Wg/ml).
2.3. Northern analysis
To analyze transcriptional induction of mkp-1 gene 500 000 cells
were plated on 10 cm dishes and after 2^3 days cells were serum-
starved and treated as indicated. Total RNA was isolated with RNA-
Zol1 B (TEL-TEST, Inc., USA), run on 1% agarose gels, and trans-
ferred to a Hybond-N nylon membrane (Amersham Pharmacia). The
membranes were hybridized with random-primed cDNA of the mkp-1
gene.
2.4. Western analysis
For the analysis of ERK phosphorylation and phosphatase expres-
sion, 250 000 cells were plated on 30 mm dishes. After 2^3 days, cells
were serum-starved and subjected to various treatments. Subse-
quently, the cells were washed once with cold phosphate-bu¡ered sa-
line (PBS), solubilized in 150 Wl of Laemmli-SDS bu¡er and sonicated
to shear the chromosomal DNA. The lysates were run on 12% SDS^
PAGE and transferred to nitrocellulose membrane (Schlei-
cherpSchuell, Germany). The membrane was incubated overnight at
4‡C under a gentle rotation in 10 mM Tris^HCl pH 8.0, 150 mM
NaCl, 0.1% Tween-20 and 5% (w/v) non-fat dry milk containing the
speci¢c antibodies. The primary antibody against active ERKs was
diluted 1:10 000, whereas the anti-ERK2, anti-phospho-p38, anti-p38
antibodies were diluted 1:4000 and antibodies for speci¢c phospha-
tases 1:500. The speci¢c bands were detected using the ECL chemi-
luminescence detection method (Amersham) by exposure on X-ray
¢lms. To study the loading of the samples, the membranes were
stripped with 0.1 M glycine (pH 2.5) (3U5 min) and washed brie£y
with 10 mM Tris^HCl pH 8.0, 150 mM NaCl and 0.1% Tween-20,
followed by blocking and immunodetection with anti-p38 or anti-
ERK2 antibodies.
2.5. Immuno£uorescent staining
For immuno£uorescent detection of dually phosphorylated ERK1
and ERK2 proteins, 5000 cells were plated on plastic coverslips
(Amersham Pharmacia). After 2 days cells were serum-starved and
treated as indicated. Cells were washed twice with cold PBS and ¢xed
with 10% paraformaldehyde in PBS at room temperature for 15 min
followed by 10 min in methanol at 320‡C. The cells were then incu-
bated with antibodies against active ERKs (1:500 in PBS containing
1% bovine serum albumin) for 16 h at 4‡C under gentle shaking,
washed three times with PBS and incubated with FITC-conjugated
secondary antibody for 1 h in the dark at room temperature. The
stainings were studied using £uorescence microscopy (Leica DMR).
2.6. ERK2 immunocomplex assay
For ERK assays 500 000 cells were plated on 10 cm dishes and after
2^3 days, cells were serum-starved and treated as indicated. Cells were
washed with cold PBS and lysed in cold RIPA bu¡er (1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA,) sup-
plemented with protease inhibitors (1 mM phenylmethylsulfonyl £uo-
ride, 100 U aprotinin, 10 mM leupeptin, 1 mM pepstatin and 1 mM
antipain) and phosphatase inhibitors (20 mM NaF and 1 mM
NaVO4). The lysates were cleared by centrifugation (10 000Ug for
10 min at 4‡C). ERK2 was immunoprecipitated with 2 Wg of the
monoclonal anti-ERK2 antibody (2 h at 4‡C) and immunocomplexes
were collected by incubating with protein-G Sepharose at 4‡C for 2 h.
The immunoprecipitates were washed ¢ve times with cold RIPA bu¡-
er and two times with cold ERK kinase bu¡er (10 mM Tris, pH 7.4,
150 mM NaCl, 10 mM MgCl2) and assayed for ERK2 activity by
incubating with 30 Wg of MBP and 2.5 WCi of [Q-32P]ATP in 30 Wl of
kinase bu¡er supplemented with 25 WM ATP at 30‡C for 30 min, after
which the reactions were terminated by boiling in SDS sample bu¡er.
The samples were run on 12% SDS^PAGE, and the gels were dried
and exposed on X-ray ¢lms. The amount of immunoprecipitated
ERK2 was analyzed by Western blotting with anti-ERK2 antibody.
2.7. Raf-1 immunocomplex assay
For Raf-1 assays 500 000 cells were plated on 10 cm dishes and
after 2^3 days, cells were serum-starved and treated as indicated. Cells
were washed with cold PBS and lysed in cold HEB bu¡er (25 mM
HEPES, pH 7.5, 10% glycerol, 5 mM EDTA, 150 mM NaCl, 0.1% L-
mercaptoethanol, 1% Triton X-100,) supplemented with protease in-
hibitors (1 mM phenylmethylsulfonyl £uoride, 100 U aprotinin,
10 mM leupeptin, 1 mM pepstatin and 1 mM antipain) and phospha-
tase inhibitors (20 mM Na-orthopyrophosphate, 50 mM NaF, 1 mM
NaVO4 and 1 mM benzamidine). The lysates were cleared by centri-
fugation (10 000Ug) for 15 min at 4‡C. The supernatants were as-
sayed for protein concentration using Bio-Rad DC Protein Assay,
and 500 Wg of protein was subjected to immunoprecipitation of
Raf-1 proteins overnight at 4‡C using 10 Wg of agarose-conjugated
Raf-1 antibody (C-12:sc-133Ac). The immunoprecipitates were
washed once with ice cold HEB bu¡er and once with ice cold LiCl
bu¡er (500 mM LiCl, 100 mM Tris, pH 7.6, 0.1% Triton X-100), and
twice with ice cold kinase bu¡er (20 mM HEPES, pH 7.5, 20 mM
MgCl2, 0.1% L-mercaptoethanol) and subjected to Raf-1 activity as-
say involving incubation with 2 Wg of puri¢ed MEK-1 and 2.5 WCi of
[Q-32P]ATP in 30 Wl of kinase bu¡er supplemented with 25 WM ATP.
The mixtures were incubated at 30‡C for 30 min and the reactions
were terminated by boiling in SDS-gel sample bu¡er. The samples
were run on the 12% SDS^PAGE, the gels were dried and exposed
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on X-ray ¢lms. Rabbit anti-Raf-1 antibody was used to verify the
equal amount of immunoprecipitated Raf-1 in the samples.
2.8. GST-pulldown assay
For GST-pulldown assays 500 000 cells expressing GST-ERK2 were
plated on 10 cm dishes, and after 2^3 days cells were serum-starved
and treated as indicated. Cells were washed with cold PBS and lysed
in GST-pulldown bu¡er (20 mM HEPES pH 8.0, 2 mM EDTA, 1%
Triton X-100, 10% glycerol, 50 mM L-glycerophosphate, 1 mM
NaVO4, 25 mM NaF) supplemented with protease inhibitors (1 mM
phenylmethylsulfonyl £uoride, 100 U aprotinin, 10 mM leupeptin,
1 mM pepstatin and 1 mM antipain). The lysates were cleared by
centrifugation (10 000Ug) for 10 min at 4‡C. The supernatants were
measured for protein concentrations using Bio-Rad DC Protein As-
say, combined with 50% glutathione-Sepharose slurry (40 Wl slurry/
800 Wg protein) and incubated under mixing for 2 h at 4‡C. The beads
were washed three times with the GST-pulldown bu¡er after which
the bound proteins were recovered by elution with 40 Wl of 2USDS
bu¡er. The GST-ERK2-bound MKP-1 was analyzed by Western-
blotting.
3. Results
3.1. Inhibition of PKA activity increases growth factor-induced
ERK activity
To study how PKA regulates the activation of the Ras/
ERK pathway, we ¢rst followed the e¡ects of modulation
of PKA activity on the growth factor-induced phosphoryla-
tion of ERKs. Pre-treatment of the cells with the PKA inhib-
itor H89 substantially increased and prolonged the phosphor-
ylation, which remained detectable as long as 9 h from the
start of the FGF-2 induction. By contrast, when the cells were
pre-treated with 8-BrcAMP, the level of ERK phosphoryla-
tion was signi¢cantly decreased (Fig. 1A, left panel). With
EGF phosphorylation of ERKs it was more transient than
that induced by FGF-2 and decreased signi¢cantly 30 min
after the initiation of the EGF stimuli. Inhibition of PKA
with H89 clearly increased and prolonged the ERK phosphor-
ylation, although the response was somewhat less prominent
than that seen with FGF-2, whereas stimulation of PKA de-
creased ERK phosphorylation (Fig. 1A, right panel). In the
absence of growth factor, H89 or 8-BrcAMP did not induce
phosphorylation of ERKs (data not shown). To ensure that
the down-regulatory e¡ect of 8-BrcAMP on the growth fac-
tor-induced activation of ERKs was mediated by PKA, we
pre-treated cells with 8-BrcAMP for 15 min, followed by a
15 min H89 treatment prior to growth factor induction (lower
panels in Fig. 1A). We further investigated the e¡ects of PKA
modulation on the catalytic activity of ERK2 by measuring
the ability of immunoprecipitated ERK2 to phosphorylate
MBP. Inhibition of PKA by H89 prior to FGF-2 induction
markedly increased the catalytic activity of ERK2, whereas
treatment with 8-BrcAMP decreased the activity (Fig. 1B).
To study whether PKA also in£uenced other growth factor-
regulated MAPK pathways, we investigated the e¡ect of PKA
modulation on the p38 pathway using antibodies against
phospho-p38. Whereas FGF-2, EGF and anisomycin were
all able to induce phosphorylation of p38, the phosphoryla-
tion was not signi¢cantly altered by modulation of PKA ac-
tivity (Fig. 1C). These data suggest that PKA may speci¢cally
control the Ras/ERK pathway.
3.2. Inhibition of PKA activity increases FGF-2-induced
nuclear localization of activated ERKs
Activated ERKs are dimerized and translocated to the nu-
cleus where they phosphorylate speci¢c substrates, including
transcription factor Elk-1, leading to activation-speci¢c genes
such as c-Fos [55^57]. To further study how PKA a¡ects the
activity of ERKs, we followed the nuclear entry and residence
of activated ERKs in cells treated with FGF-2 and the mod-
ulators of PKA activity. Immuno£uorescent studies with anti-
phospho-ERK1/2 antibodies revealed that inhibition of PKA
activity increased the nuclear entry and prolonged the nuclear
residence of activated ERKs (Fig. 2I^L). By contrast, when
the cells were pre-treated with 8-BrcAMP the nuclear staining
was almost completely abolished (Fig. 2M^P). These results
are in good agreement with the observations of how PKA
regulated the FGF-2-induced phosphorylation and catalytic
activity of ERKs. Our results likely represent PKA dependent
changes in FGF-2-induced ERK activation. However, we note
Fig. 1. PKA regulates growth factor-induced activity of ERKs.
NIH3T3 cells were serum-starved and treated with PKA inhibitor
H89 or PKA activator 8-BrcAMP for 30 min prior to stimulation
with (A) FGF-2 or EGF. Phosphorylation of ERKs was detected
by anti-phospho-ERK1/2 immunoblot of total cell lysates (P*-
ERK1/2). The loading of the samples was studied by immunoblot-
ting with anti-ERK2 antibodies. The immunoblots representing the
di¡erent treatments were exposed on the same ¢lm for comparabil-
ity of the data. B: Autoradiogram showing phosphorylation of
MBP by immunoprecipitated ERK2. The amount of immunopreci-
pitated ERK2 protein in the samples was studied with anti-ERK2
immunoblot. C: Cells were treated with FGF-2, EGF or anisomycin
(anisom; 2 Wg/ml) alone or in combination with PKA modulators.
Phosphorylation of p38 was assessed by immunoblotting with anti-
bodies against activated p38 (P*-p38). All these experiments were re-
peated at least three times with similar results.
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that PKA has been proposed to regulate the nuclear entry of
ERKs in neuronal cells [58] and serum response factor in
¢broblasts [59], raising an alternative possibility that deregu-
lated PKA activity would a¡ect the nuclear transport of acti-
vated ERKs in a more direct fashion.
3.3. Inhibition of PKA activity increases growth factor-induced
activity of Raf-1
cAMP and PKA have been shown to activate the Ras/ERK
pathway via B-Raf, whereas inhibition is mediated through
PKA-speci¢c phosphorylation of Raf-1 proteins [7,15,16,18,
60^62]. Since previous reports and our studies (data not
shown) suggest that cAMP and PKA do not activate the
Ras/ERK pathway in NIH3T3 ¢broblasts, we studied the ef-
fects of PKA modulation on the catalytic activity of Raf-1.
Raf-1 was immunoprecipitated from cells treated with FGF-2,
EGF and PKA modulators, and analyzed for its ability to
phosphorylate MEK-1. Inhibition of PKA activity prior to
FGF-2 stimulation signi¢cantly increased and prolonged the
Raf-1 activity, whereas treatment of cells with 8-BrcAMP al-
most completely abolished Raf-1 activation (Fig. 3A). PKA
also regulated the Raf-1 activation induced by EGF, although
the maximal e¡ect of PKA inhibition was seen earlier than in
cells stimulated with FGF-2 (Fig. 3B). These results indicate
that a basal PKA activity may be required to adjust the acti-
vation level of Raf-1.
3.4. Regulation of MKP-1 expression by PKA and growth
factors
Given the ¢ndings that MKP-1 and MKP-2 are encoded by
growth factor-responsive immediate early genes [30,35,63] and
that cAMP regulates the transcription of mkp-1 gene [50^52],
Fig. 2. E¡ect of PKA activity on nuclear entry and residence of activated ERKs. Cells were grown on class coverslips, serum-starved and left
untreated (A^D), treated with FGF-2 alone (E^H) or in combination with modulators of PKA activity (I^P). After the indicated time points
the cells were ¢xed and stained with a monoclonal antibody against activated ERKs. The localization of activated ERKs was analyzed using a
£uorescence microscope (Leica 4D). The experiment was repeated three times with similar results, representative pictures are shown.
Fig. 3. Inhibition of PKA activity increases the growth factor-in-
duced activation of Raf-1. Autoradiograms demonstrating phos-
phorylation of MEK-1 by immunoprecipitated Raf-1. Cells were se-
rum-starved and treated with (A) FGF-2 or (B) EGF alone or in
combination with H89 (H=H89) or 8-BrcAMP (c= 8-BrcAMP).
After indicated time points the cells were lysed and the lysates were
subjected to immunoprecipitation with agarose-conjugated Raf-1
antibodies followed by kinase reactions using MEK-1 as substrate.
The amount of immunoprecipitated Raf-1 in the samples was ana-
lyzed by anti-Raf-1 immunoblot. MEK-1*, phosphorylated MEK-1;
WB, Western blot. The experiment was repeated three times with
similar results.
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we investigated how PKA a¡ects the growth factor-induced
expression of these two phosphatases. In addition, we studied
the expression of MKP-3, although it is not encoded by an
immediate early gene [64].
Immunoblotting with anti-MKP antibodies (Fig. 4A) indi-
cated that FGF-2 rapidly induced the expression of MKP-1.
Pre-treatment of cells with H89 decreased and delayed the
expression of MKP-1, such that the protein was detectable
not until 2 h after the start of the FGF-2 induction. Con-
versely, when PKA was activated with 8-BrcAMP prior to
FGF-2 stimuli, the expression of MKP-1 increased signi¢-
cantly. The expression of MKP-2 appeared very low and
was not in£uenced by FGF-2 or modulation of PKA activity,
whereas the expression of MKP-3 was increased in response
to FGF-2, although the induction was clearly delayed. Inter-
estingly, the MKP-3 expression appeared to be regulated by
PKA, but it di¡ered from that seen for MKP-1, since both
stimulation and inhibition of PKA activity decreased the ex-
pression. In EGF-stimulated cells, PKA regulated the expres-
sion of MKPs in a largely similar fashion than in FGF-2-
treated cells, although the expression of MKP-1 following
the PKA activation was more transient (Fig. 4B).
To show that protein synthesis was required for the ERK
dephosphorylation, cells were pre-treated with cycloheximide
and analyzed for FGF-2-induced ERK phosphorylation by
immunoblotting. The results (Fig. 4C) showed that cyclohex-
imide abolished the FGF-2-induced expression of MKP-1 and
consequently prevented the dephosphorylation of ERKs.
These results demonstrate that PKA controls the growth fac-
tor-induced expression of MKP-1, and con¢rms that the de-
phosphorylation of ERKs requires growth factor-induced
protein synthesis.
3.5. Up-regulated expression of MKP-1 enhances formation of
MKP-1/ERK2 complexes and dephosphorylation of ERK2
To study whether the PKA-mediated regulation of MKP-1
expression would a¡ect the complex formation between the
activated ERKs and MKP-1, we established NIH3T3 cell lines
Fig. 4. PKA regulates growth factor-induced production of MKP-1
protein. Serum-starved cells were treated with H89 or 8-BrcAMP
for 30 min prior to growth factor stimulation. The expression of
MKPs was studied from total cell lysates by immunoblotting with
antibodies against the di¡erent phosphatase species. Immunoblots
with anti-MKP-1, anti-MKP-2 and anti-MKP-3 antibodies of lysates
from (A) FGF-2- and (B) EGF-treated cells. (C) Serum-starved cells
were treated with cycloheximide for 10 min (chx; 10 Wg/ml) prior to
FGF-2 stimulation. Phosphorylation of ERKs was studied by im-
munoblotting with anti-phospho-ERK1/2 antibodies. To correlate
the expression level of MKP-1 to the amount of phosphorylated
ERKs, the membranes were stripped and re-probed with anti-
MKP-1 antibodies. The loading of the samples was studied by im-
munoblotting with anti-ERK2 antibodies. Each type of experiment
was repeated three times with similar results.
Fig. 5. PKA-mediated up-regulation of growth factor-induced
MKP-1 expression increases complex formation between MKP-1
and ERK2. A: Immunoblots from wild-type and pEBG-GST-
ERK2-transfected NIH3T3 cells showing the expression levels and
growth factor-induced phosphorylation of the GST-ERK2 protein.
B: To study the association of MKP-1 with ERK2 di¡erentially
treated cells were lysed in GST-pulldown bu¡er after which GST-
ERK2 proteins were recovered using glutathione-Sepharose beads.
The glutathione-Sepharose-bound GST-ERK2, along with associated
proteins, was eluted using SDS bu¡er. The association of MKP-1
with GST-ERK2 was investigated with anti-MKP-1 immunoblots.
The amount of GST-ERK2 protein in the samples was studied by
anti-ERK2 immunoblot. The expression level of the MKP-1 protein
was studied from cell lysates (30 Wg of protein) by immunoblotting
with anti-MKP-1 antibodies. C: Immunoblots from 3T3 cells stably
expressing GST protein (3T3/GST), showing no association of
MKP-1 protein with the GST protein. Each type of experiment was
repeated three times with similar results.
FEBS 26183 7-6-02
J.-P. Pursiheimo et al./FEBS Letters 521 (2002) 157^164 161
with low constitutive expression of GST-ERK2 fusion protein
(3T3/GST-ERK2) (Fig. 5A).
The interaction between MKP-1 and GST-ERK2 fusion
protein was studied by GST-pulldown assays followed by im-
munoblotting with anti-MKP-1 antibodies. Activation of
PKA prior to FGF-2 stimuli increased the expression of
MKP-1 protein, and consequently the amount of GST-
ERK2-bound MKP-1 and dephosphorylation of GST-
ERK2, whereas inhibition of PKA activity abolished the ex-
pression as well as the binding and dephosphorylation
(Fig. 5B). Notably, the complex formation between MKP-1
and GST-ERK2 correlated to the expression level of MKP-1.
Pulldown assays with the cells producing only the GST part
of the fusion protein (3T3/GST) did not yield MKP-1 protein,
showing that the binding required ERK2 (Fig. 5C). These
data suggest that, by regulating the growth factor induced
expression of MKP-1, PKA would control the complex for-
mation between ERKs and MKP-1 and subsequently the de-
phosphorylation of ERKs.
3.6. PKA and Ras/ERK pathways co-operatively regulate
expression and stability of MKP-1 protein
We next investigated the mechanisms by which PKA and
growth factors co-operatively regulate the expression of mkp-1
gene and the production of MKP-1 protein. In agreement
with previous data [50,51], activation of PKA by 8-BrcAMP
clearly increased the transcriptional activity of mkp-1 gene
whereas growth factor stimulation had only a weak e¡ect
on the transcription. In cells treated with both 8-BrcAMP
and growth factors, the levels of MKP-1 mRNA remained
similar than in cells treated with 8-BrcAMP alone (Fig. 6A).
Inhibition of PKA activity prior to growth factor treatment
abolished the transcription, indicating that PKA is required
for growth factor-mediated activation of the mkp-1 gene. Ac-
tivation of PKA alone did not induce production of MKP-1
protein, whereas the combined 8-BrcAMP/growth factor
treatment signi¢cantly increased the amount of MKP-1 pro-
tein (Figs. 4A,B and 6B). These ¢ndings suggest that in addi-
tion to a weak transcriptional induction, the growth factor
signals also regulate the stability of the MKP-1 protein. Bron-
dello and co-workers recently reported that ERK-mediated
phosphorylation of MKP-1 increased its stability by decreas-
ing ubiquitin-directed proteolysis [33]. To investigate whether
the absence of MKP-1 protein product upon PKA activation
was due to rapid ubiquitin-mediated degradation we used
MG132 to block the proteasome pathway. As shown in
Fig. 6B, treatment of cells with 8-BrcAMP and MG132 led
to a massive accumulation of MKP-1 protein. Our data thus
suggest that PKA activation alone is su⁄cient to induce pro-
duction of MKP-1 protein, but that the protein product is
rapidly degraded by ubiquitin-directed proteolysis in the ab-
sence of growth factor-mediated stimulation of the Ras/ERK
pathway to stabilize the protein.
To con¢rm that the accumulation of the MKP-1 protein in
growth factor-stimulated cells required co-operative function
of the PKA and Ras/ERK pathways, we established NIH3T3
cell lines with stable expression of a fusion protein where the
ligand binding domain of human estrogen receptor was com-
bined to the catalytic domain of Raf-1 (vRaf-1:ER[DD]). In
this system the Ras/ERK pathway can be activated by 4-OHT
without a¡ecting other signaling pathways [65,66]. Impor-
tantly, although PKA has been shown to in£uence Raf-1 ac-
tivity upon growth factor stimulation, it did not a¡ect the 4-
OHT-induced activity of the vRaf-1:ER[DD] fusion protein
(data not shown). The 4-OHT-induced activation of the Ras/
ERK pathway was rather slow, requiring prolonged 4-OHT
induction to yield a level of ERK phosphorylation compara-
ble to that obtained by growth factor stimulus. The results
indicated that whereas 4-OHT alone had only a weak e¡ect
on MKP-1, concomitant activation of PKA signi¢cantly in-
creased the accumulation of the MKP-1 protein (Fig. 6C).
These data con¢rm the idea that besides PKA-induced tran-
scription of mkp-1 gene the growth factor-induced activation
of the Ras/ERK pathway is required for the stabilization of
the MKP-1 protein.
Fig. 6. PKA-mediated regulation of growth factor-induced expres-
sion of MKP-1. A: Serum-deprived cells were treated with 8-
BrcAMP, H89 and growth factors alone or in combination followed
by Northern analysis of MKP-1 and GAPDH mRNAs. B: Cells
were treated with the proteasome inhibitor MG132 (10 WM) prior
to PKA activation (8-BrcAMP) or growth factor inductions. Accu-
mulation of MKP-1 was investigated with anti-MKP-1 immunoblots
of total cell lysates. The loading was studied with anti-ERK2 immu-
noblot. C: Serum-starved NIH3T3 cells expressing the vRaf-
1:ER[DD] fusion protein were pre-treated with 100 nM 4-OHT for
12 and 24 h followed by treatment with 8-BrcAMP (500 WM) for
indicated times. To block the activation of Ras/ERK pathway
PD98059 (20 WM) was introduced to the cells 30 min prior to FGF-
2 induction or at the same time as 4-OHT. MKP-1 expression was
studied by anti-MKP-1 immunoblots from total cell lysates. Several
experiments were performed using both 12 and 24 h 4-OHT stimuli
and the results from representative experiments are shown. To dem-
onstrate that the vRaf-1:ER[DD] fusion protein was functional the
membranes were stripped and blotted with antibodies against phos-
phorylated ERK1/2 and human estrogen receptor (ERK). The load-
ing was studied with anti-ERK2 immunoblot. These experiments
were repeated at least three times with similar results, representative
experiments are shown.
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4. Discussion
Recent studies have demonstrated that increased PKA ac-
tivity down-regulates the activity of the Ras/ERK pathway,
suggesting a role for PKA in the regulation of growth factor
signaling. However, important questions regarding the phys-
iological signi¢cance of PKA in the regulation of the Ras/
ERK signaling remain unanswered. In this paper we present
data to support the idea that PKA has a central role in the
growth factor signaling, and provide evidence for the impor-
tant role of the basal PKA activity in such regulation. In these
studies we have employed H89 to inhibit PKA activity.
Although H89 is widely used to inhibit PKA signaling, we
note that it may not be entirely PKA-speci¢c since recent
studies have shown its ability to down-regulate MSK1 and
RSK2 [67,68]. In some situations the H89-mediated e¡ects
may be directed, at least partly, via these kinases but the
results shown in this paper are clearly dependent on down-
regulation of PKA activity.
We recently reported that in NIH3T3 cells the activation of
PKA is regulated by FGF-2 and further that active PKA is
required for the activation of growth factor-induced transcrip-
tion and cell proliferation [54]. NIH3T3 cells display detect-
able basal PKA activity which may regulate the magnitude of
growth factor signals, perhaps by maintaining a threshold
which must be overcome before activation of signal transduc-
tion. When the threshold is overcome PKA would control the
signal strength by down-regulating the Raf-1 activity and by
increasing the MKP-1 expression, thus providing an e¡ective
mechanism to limit ERK activity. Our data thus point to a
tight functional relationship between growth factor signaling
and PKA.
Our results indicate that by blocking the PKA activity prior
to growth factor stimulus Raf-1 activity was signi¢cantly in-
creased, whereas PKA activation abolished the activation of
Raf-1, conforming to the previous notion that PKA regulates
the growth factor-induced activity of Raf-1 in a predomi-
nantly negative fashion. The regulation is thought to involve
direct phosphorylation of Raf-1 by PKA [60^62,69]. However,
the regulatory mechanisms are incompletely understood be-
cause Raf proteins contain several putative phosphorylation
sites and are di¡erentially regulated in di¡erent model systems
[70]. PKA has been proposed to down-regulate PDGF-in-
duced ERK activation by inducing MKP-1 [71]. Here we pro-
vide evidence that the Ras/ERK pathway and PKA co-oper-
atively regulate the expression and function of MKP-1 protein
and further that MKP-1 is critical for the PKA-mediated reg-
ulation of the Ras/ERK signaling. MKP-1 expression is in-
duced by growth factors in a variety of cell types suggesting a
negative feedback loop down-regulating the signaling through
the Ras/ERK pathway [35^37,39,40]. The role of PKA in this
loop may be to adjust and enhance the down-regulatory ef-
fect. Such mechanisms provide an e¡ective way to rapidly
dephosphorylate nuclear ERKs and limit the growth factor
signaling close to its end point, in the nucleus.
How does PKA regulate the expression of mkp-1 gene? The
transcription of mkp-1 gene is regulated by two CRE sites in
its promoter region that work together with an E-box element
[52]. PKA activation induces binding of CREB proteins to the
CRE sites and forms, together with E-box-bound USF pro-
teins, a complex able to promote transcription of the adjacent
gene. This explains why PKA alone is su⁄cient to induce
transcription of mkp-1 gene. By contrast, growth factor stim-
ulation appears a weak activator of the mkp-1 gene (Fig. 6A).
Kwak and co-workers showed that the basal promoter region
does not mediate the growth factor signals since the 800 bp
region containing the transcriptional initiation site responds
poorly to FGF-2 or EGF [34]. Instead, the Ras/ERK pathway
appears to be critical for the regulation of MKP-1 protein
turnover, presumably involving phosphorylation of serine res-
idues 359 and 364 preventing the ubiquitin-mediated degrada-
tion [33]. Our data suggest that even a weak signal via the
Ras/ERK pathway after PKA-mediated down-regulation of
Raf-1 activity is su⁄cient to stabilize the MKP-1 protein lead-
ing to e⁄cient accumulation of MKP-1 and dephosphoryla-
tion of ERKs.
In summary, our data indicate that PKA may secure the
growth factor-induced signaling by balancing the activity level
of the Ras/ERK pathway. The balancing e¡ect is mediated by
regulating the activity of Raf-1 and the expression and stabil-
ity of MKP-1. In particular, our results suggest an important
role for the basal PKA activity in such regulation. The mech-
anism proposed may be involved in the maintenance of a
physiologically relevant level of ERK activity, and moreover
this PKA-mediated regulation might function as a back up
mechanism to ensure that speci¢c growth factors elicit proper
responses in target cells.
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